biomarker

Clinical Trial End Points in ADPKD

June 6, 2019 // 0 Comments

Despite our current understanding regarding the pathophysiology of autosomal dominant polycystic kidney disease (ADPKD), only one therapy has been approved by the US FDA. There has been recent interest in redefining end points for clinical trials [read more...]